Efficacy and Safety of Dalbavancin As Suppressive Therapy

NCT06899906 · clinicaltrials.gov ↗

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Efficacy and Safety of Dalbavancin
In Subjects Who Received SAT with DAL
For Acute or Chronic Infections Between July 2019 and December 2024

Interventions

OTHER: Determine patient demographic and clinical characteristics at baseline

Sponsor

Hospices Civils de Lyon